FDA approves first generics of Lyrica
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
Bearish Options Positioning in Teva Pharma (TEVA) Targets Downside in Shares Through January -Susquehanna
July 22, 2019 1:48 PM EDTSusquehanna options strategist Alison Edwards notes bearish options positioning in Teva Pharma (NYSE: TEVA), as investors bought 22k Jan 9 Puts for $2.10. The investors buy volatility, suggesting the shares have an increased probability to trade below their breakeven of ~$6.90 (-10%).
... More
